Advertisement
U.S. Markets closed

Nova Mentis Life Science Corp. (NMLSF)

Other OTC - Other OTC Delayed Price. Currency in USD
0.0140+0.0019 (+15.70%)
At close: 12:10PM EDT
Full screen
Loading interactive chart...
  • Newsfile

    Nova Mentis Announces Change of Directors

    Vancouver, British Columbia--(Newsfile Corp. - February 26, 2024) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company") announces the appointment of Steve Loutskou to the Company's Board of Directors, effective February 23, 2024.Mr. Loutskou, a seasoned serial entrepreneur, boasts a career spanning over 20 years, marked by numerous success stories. From the initiation of early-stage start-ups to steering them through mature commercialization phases, he

  • Newsfile

    Nova Mentis Applauds Government Decision to Create Rare Disease Advisory Group

    Vancouver, British Columbia--(Newsfile Corp. - November 3, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased the Canadian government has established a new Implementation Advisory Group (IAG) for drugs for rare diseases, as part of its National Strategy to help facilitate informatio

  • Newsfile

    Nova Mentis Announces Participant Screening Underway in Canada's First Psilocybin Clinical Trial for Fragile X Syndrome

    Vancouver, British Columbia--(Newsfile Corp. - August 30, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to provide an update on its Phase IIA clinical trial testing psilocybin for the treatment of fragile X syndrome (FXS), the leading genetic cause of autism spectrum disorder (